The Case: Diagnosed Between Visa and AIMA
The situation surfaced on r/PortugalExpats on April 14, 2026. A US retiree and their spouse had their VFS appointment in San Francisco on January 21 and received their Portuguese D7 visas on April 3. In the account posted to the subreddit, the applicant explained that between those two dates, they were hospitalised with an autoimmune condition that caused serious kidney problems. They had spoken with their lawyer in February about the expected costs of ongoing medication, lab work, and doctor visits, and those costs — at the time — were similar to what they paid in the United States under their existing health insurance. Their plan to move to Portugal seemed intact.
Then the treatment plan changed. The post continues: the applicant's doctors, seeing that the initial medication was not producing the expected improvement, recommended switching to a different drug. When the lawyer was re-consulted, the new information arrived: "this new medication alone will cost between 3000-5000 euros/month." The AIMA appointment — the appointment required to issue the physical residence card that triggers MGEN eligibility and reliable SNS access — was not until December. The gap between receiving the D7 visa and obtaining functioning healthcare coverage in Portugal had widened from a theoretical inconvenience into a five-figure monthly liability.
The thread drew 10 comments within a day, most from other D7 holders or immigration professionals who recognised the pattern. It is not the first time this type of case has surfaced on the Portuguese expat forums, and the structural issue behind it applies to every new arrival whose health changes between receiving their visa and completing the AIMA process. For wealthy retirees choosing Portugal in part because of its reputation for accessible healthcare, the reality of the AIMA backlog has introduced an intermediate risk period that the marketing materials do not discuss.
Why Medication Costs Changed So Dramatically
The cost change in this case is typical of what happens when a new-generation specialty medication enters the treatment plan. Specialty biologics and targeted immunosuppressants used for autoimmune conditions — particularly those affecting the kidneys — routinely carry list prices above EUR 3,000 per month, with some newer agents reaching EUR 5,000 to EUR 8,000 per month. In both the United States and in Portugal, these prices are rarely paid in cash by an insured patient; they are mediated through insurance formularies, SNS reimbursement structures, or pharmaceutical manufacturer patient-access programmes. When an individual is caught in a coverage gap, the cash price is the effective price.
For a US resident transitioning to Portugal, the cost differential is not that Portuguese pharmacy cash prices are higher than US cash prices — they are usually somewhat lower — but that US health insurance or Medicare would have absorbed most of the cost, while in Portugal the equivalent coverage has not yet been established. The D7 visa in the passport is evidence of legal permission to enter and settle, but it does not immediately translate into SNS enrolment or MGEN coverage. Until the AIMA appointment is complete and the residence card is issued, the patient sits in an intermediate status that looks like residence on paper and like medical tourism in the healthcare system.
There is no simple workaround at the pharmacy counter. The new specialty drug will be dispensed against a valid Portuguese prescription, but without SNS eligibility, the patient pays the full cash price. Patient-assistance programmes from pharmaceutical manufacturers do exist in Portugal, but they are typically structured for chronic patients in the SNS system rather than short-term unreimbursed cases. For a retiree transitioning from the United States, the practical effect is a several-month exposure at cash prices while the administrative apparatus catches up.
What SNS and MGEN Would Have Covered
The Portuguese public health system (SNS) operates as the primary access point for chronic care in Portugal. Once a resident is enrolled, most specialty consultations and medications are available at significantly reduced cost. Biologic and immunosuppressant medications for conditions such as autoimmune kidney disease are covered under the SNS hospital pharmacy dispensing pathway, with the patient paying only the user charge (typically EUR 5 per hospital pharmacy visit, with some conditions fully exempt). For a patient with established SNS eligibility and a specialist referral, the out-of-pocket cost of the same medication that was quoted at EUR 3,000 to EUR 5,000 per month cash would be dramatically lower.
Mútua Geral Nacional (MGEN) is a complementary health scheme available to Portuguese residents that covers a range of services, including private-sector specialist consultations, dental care, and certain pharmaceutical costs. MGEN supplements SNS rather than replaces it. Enrolment typically requires proof of Portuguese legal residence and produces coverage within a short administrative window once enrolment is complete. For the D7 applicant in the Reddit case, MGEN enrolment depends on obtaining the physical residence card first — which depends on the December AIMA appointment.
The combined SNS + MGEN coverage that most settled expats in Portugal rely on for chronic care simply does not exist in the intermediate window between D7 visa issuance and residence card issuance. This is not a policy failure in the sense that the systems were deliberately designed this way; it is an operational consequence of AIMA's processing timeline misaligning with the healthcare system's eligibility gates. The gap is real and the exposure is significant.
The Expedite Path for Medical Hardship
AIMA operates an internal process for expedite requests on medical and humanitarian grounds. The criteria are narrow — the agency does not expedite based on personal convenience or financial inconvenience alone — but cases involving a documented medical diagnosis, a specific treatment plan, and a demonstrated causal link between the AIMA delay and ongoing harm to the applicant's health do qualify for consideration. The request is submitted through the AIMA contact form with supporting documentation attached. Processing time for an expedite decision is typically three to six weeks, and the outcome is either an earlier appointment or a formal denial.
For the case on r/PortugalExpats, the expedite documentation package would ideally include the hospital discharge summary from the autoimmune-related admission, a written statement from the Portuguese specialist (either attending physician or a specialist who has taken over the case in Portugal) documenting the diagnosis and the recommended treatment regimen, correspondence from the immigration lawyer summarising the legal basis for the expedite request, and documentation showing the financial exposure — pharmacy quotes for the medication at cash price, with a calculation of the out-of-pocket cost during the waiting period. A strong package with specific numbers produces better outcomes than a general plea.
Beyond the AIMA expedite, a parallel path is judicial intervention through an administrative subpoena, also known as intimação. When the AIMA delay is causing documented harm and the statutory decision period has been exceeded, the administrative court can order AIMA to issue a decision within a defined timeframe — typically 60 to 90 days. For a D7 holder whose AIMA appointment is set for December but whose visa was issued in April, the statutory timeline may not yet have been exceeded, so the subpoena route is less immediately available than the expedite request. See the filing process for judicial action against AIMA for the full mechanical steps.
Private Insurance Gaps for New D7 Holders
Most D7 applicants arrive in Portugal with a private health insurance policy taken out specifically to satisfy the visa requirement. These policies are generally designed to cover emergency care and routine outpatient visits up to a defined annual cap, typically around EUR 30,000 to EUR 50,000. For a straightforward transition year — no major diagnoses, no hospitalisations, no specialty medications — the policies work as advertised. For a transition year that includes a chronic-disease diagnosis and a high-cost medication, the policies have three structural gaps.
The first gap is the pre-existing condition exclusion. Most policies require the applicant to declare any pre-existing condition on the application and will either exclude that condition from coverage or charge a surcharge. A diagnosis made shortly after arrival creates a question about when symptoms first appeared; insurers will typically request US medical records to determine whether the condition was present before policy inception. For genuinely new diagnoses, coverage applies, but the claims review process can add months of delay while records are transferred internationally.
The second gap is the annual coverage cap. For a chronic condition requiring EUR 3,000 to EUR 5,000 in monthly medication, a EUR 30,000 annual cap is exhausted within six to ten months. Even if the policy accepts the condition as covered, the exposure beyond the cap reverts to the patient. For the case on r/PortugalExpats, the eight-month gap until the December AIMA appointment would likely exhaust any standard D7 policy cap if the medication is covered at all.
The third gap is the waiting period for chronic conditions. Most policies include a six to twelve month waiting period before chronic-condition coverage begins. Depending on when the diagnosis is made and when the policy inception date was, the waiting period may or may not be fully served by the time the medication is needed. For new D7 arrivals, the safest assumption is that the private insurance taken out for the visa will not comfortably cover a high-cost chronic diagnosis during the AIMA waiting period, and that supplementary coverage — either through upgrading the policy, through a separate specialty-condition rider, or through direct SNS enrolment once eligibility is established — needs to be secured as quickly as possible.
What Others in Similar Situations Should Do
For a D7 holder in the Reddit case's position, the action list has six steps. First, document the medical situation thoroughly with a Portuguese specialist — not just a clinical note but a formal letter on hospital or clinic letterhead that identifies the diagnosis, the required treatment, and the cost exposure if treatment is delayed. This letter is the foundation for every subsequent step. Second, consult the immigration lawyer and submit an AIMA expedite request through the contact form, attaching the specialist letter and a summary of the financial exposure. Expedite requests without specific medical documentation are routinely ignored; requests with documented medical need are reviewed seriously.
Third, pursue SNS enrolment even before the residence card is issued. Legal residents in Portugal have the right to SNS registration through their local centro de saúde, and the argument that a D7 visa holder who has entered the country and taken up residence is a legal resident is sound. Health centre staff often ask for a physical card as a default, but a lawyer's letter confirming the legal basis typically resolves the question. Once the user number (número de utente) is issued, SNS hospital pharmacy access becomes available for covered medications, which can reduce the cost exposure dramatically.
Fourth, review the existing private insurance policy with a broker to determine whether upgrading to a higher cap or adding specialty-condition coverage is feasible. Some Portuguese brokers offer bridging policies specifically designed for the AIMA waiting period. Fifth, explore pharmaceutical manufacturer patient assistance programmes. Some specialty medications offered in Portugal have manufacturer programmes that provide the drug at reduced cost for patients awaiting full system enrolment. The specialist prescribing the medication is the best point of contact for these programmes.
Sixth, if the AIMA appointment delay is material to the medical outcome, consider whether judicial intervention is appropriate. The legal rights framework while waiting for AIMA covers the statutory deadlines and the conditions under which an administrative subpoena can compel a decision. For D7 holders whose visa was issued only weeks before the medical event, this path may not yet be available, but for holders whose cases have been pending longer, it is an option that should be evaluated directly with a lawyer.
Frequently Asked Questions
Can a D7 holder access Portuguese SNS public healthcare before their AIMA appointment?
In principle yes — legal residents in Portugal, including D7 visa holders who have entered and taken up residence, have the right to register with SNS through their local centro de saúde and receive a user number. In practice, health centres often request a physical residence card or NIF registration before issuing the number, creating a gap for holders who have entered on their visa but not yet completed the AIMA appointment. A lawyer's letter confirming the legal residence status usually resolves this.
Does private Portuguese health insurance cover pre-existing conditions diagnosed shortly after arrival?
Most standard policies include a six to twelve month waiting period for chronic conditions and exclude pre-existing conditions declared on the application. For conditions diagnosed immediately after arrival, the insurer's position depends on when symptoms first appeared. If the diagnosis is clearly after policy inception with no prior symptoms, coverage should apply, but expect the insurer to request US medical records as part of the claims review.
Can AIMA expedite an appointment for medical hardship?
AIMA operates an internal expedite process on medical and humanitarian grounds. Criteria are narrow, but requests supported by a specialist's written diagnosis, a specific treatment plan, and documentation showing direct harm from the delay have a reasonable success rate. Submit through the AIMA contact form with supporting documents attached. Expedite decisions are typically issued within three to six weeks.
What does MGEN cover and when does it start?
MGEN is a complementary health scheme available to Portuguese residents that covers private specialist consultations, dental, and certain pharmaceutical costs, supplementing SNS rather than replacing it. Eligibility typically requires a valid Portuguese residence permit, meaning D7 holders cannot rely on MGEN until after their AIMA appointment and issuance of the physical residence card. Enrolment after eligibility is administratively straightforward but not retroactive.
What pharmacy cash prices apply to expensive medications for D7 holders without SNS coverage?
Portuguese pharmacy cash prices are typically lower than US cash prices for the same drug, but for newer specialty medications the price may still be in the thousands of euros per month. SNS-negotiated prices are significantly lower. For a D7 holder without SNS coverage, the effective cost is the cash price with no reimbursement, which is why establishing SNS access or pursuing an AIMA expedite becomes economically significant for chronic-condition cases.